The US National Institutes of Health (NIH) supports basic and applied biomedical research by funding grants and contracts. To measure the outcomes and impact of their programs, NIH staff conduct program evaluations and undertake targeted investigations of research portfolios. Recently, the NIH launched the electronic scientific portfolio assistant (eSPA), a web-based analytics system based on linked scientific databases that provides quantitative information for program officers and planning and evaluation officials managing research portfolios. This system has improved the ability to create and collaboratively refine research portfolios, has reduced the time needed to collect and link outcomes data such as publications and patents, and is providing information used to support research management decisions. After describing the eSPA system, we provide examples of three eSPA evaluation projects that illustrate the impact of this system on NIH evaluation objectives.
Introduction
US federal research funding agencies have been working to implement processes to better evaluate the performance and impact of their research portfolios. This has been driven in large part by implementation of the Government Performance Results Act (US Congress 1993; Committee on Science, Engineering, and Public Policy (COSEPUP) 1999 (COSEPUP) , 2001 , and subsequently by the Program Assessment and Rating Tool (Cozzens 2007) . Among the research agencies, the NIH is a mission-oriented agency with a portfolio containing both basic and applied biomedical research. The NIH mission statement lays out goals to improve programmatic decision-making on NIH-funded biomedical research, increase the efficiency and analysis of portfolio evaluation efforts, and improve the transparency and accountability of reporting and programmatic decision processes. Key to the effort to reach these goals is the participation of NIH planning and evaluation (P&E) officers and also program officers, who have core roles and responsibilities including oversight of grants, portfolio analysis and evaluation, and efficient and transparent portfolio collaboration and coordination.
To enhance the ability of program officers to perform portfolio analyses, the NIH sought to improve the efficiency of the evaluation processes including data collection on portfolio outputs and impacts. It is well understood that there are major data challenges to overcome before agency research investments can be connected with outputs and outcomes (Hicks 2010; Lane and Bertuzzi 2010) . Other challenges lie in the logical modeling of programs (McLaughlin and Jordan 1999) , determining appropriate indicators and methods of measuring impact (Smith and Sweetman 2009) , and mapping the pathways of discovery that connect basic research with improved public health (Cozzens 2010; Lewison 2003; Manning et al. 2004; Sung et al. 2003; UK Evaluation Forum 2006) .
A number of studies have demonstrated that using multiple data sources to derive performance measures provides for a robust analysis of program and research impact and improves the validity and reliability of conclusions (Bozeman et al. 1999; Georghiou and Roessner 2000; Ismail et al. 2009; Marjanovic et al. 2009; Ruegg and Feller 2003) . An early proof-of-concept project tested methods to improve NIH research portfolio evaluation by bringing together NIH funding and publication data (Boyak and Bo¨rner 2003) . Similarly, the National Institute of Environmental Health Sciences developed the scientific publication information retrieval system (SPIRES) to systematically link NIH grants to publications.
1 SPIRES data have been incorporated into the NIH electronic research administration (eRA), and made available to the public through the NIH RePORTER website.
2 However, while publication counts are important in research evaluation they provide information on only one program output.
We sought to establish whether or not a broader set of indicators could be effectively calculated and incorporated into the NIH research management process. Our objectives in developing electronic Scientific Portfolio Assistant (eSPA) were to provide program officers with streamlined access to currently available data and new data sources, and to enhance the processing of an expanded data set in a manner that exposed new relationships, perspectives, and insights into the technical merit, scientific, and social importance of NIH-funded research. These key evaluation criteria were defined by Weinberg (1963) and are reflected in Government Performance and Results Act (GPRA) quality, relevance, and leadership evaluation criteria.
The eSPA system automates the linkage between NIH grants administration data, publication and citation data, inventions, and patent data. The eSPA data infrastructure is coupled with a flexible analytic interface that provides users with the ability to perform empirical investigations of the relationships between program design and impact, which is important for understanding the factors influencing the innovation process. Taken together, the eSPA system data and analytic interface support the research evaluation objectives outlined by Marjanovic et al. (2009) , namely to increase accountability, to steer the research process to desired outcomes, to provide a means for advocacy, and to act as an input to the research management process.
This paper is structured as follows: First, we describe the indicators tested, and then how automation was applied to derive indicators from multiple data sources for implementation in the eSPA system. Finally, we present analyses performed using eSPA illustrating its use in supporting research evaluation objectives.
Development of the eSPA system
In developing eSPA, our objective was to demonstrate the technical feasibility of an automated research management system to augment the decision-making process of program managers. We started by creating a proof-ofconcept system. We defined research outputs and outcomes broadly applicable across the NIH, identified measurable proxy indicators, and established the availability of electronic data sources for each indicator. We worked with the National Institutes of Allergy and Infectious Diseases (NIAID), a component of the NIH, to create a test portfolio of research projects.
3 Grant data were obtained from the NIH information management, planning, analysis, and coordination (IMPAC II) grants database. 4 We explored opportunities for automating collection of indicator data for research projects, and developed a set of standard interactive reports and charts. The proof-of-concept was expanded to a web-based production system and launched for use at NIH in 2008. By 2010, eSPA had over 1,200 NIH users across all institutes and centers, primarily among the program and P&E community.
eSPA was developed to allow NIH staff to dynamically analyze and visualize the composition and outputs of grant portfolios. Program officers use eSPA to analyze portfolios of projects by building scatter charts, histograms, networks and other graphs to visualize the results of grantee activities. While no single indicator provides a definitive assessment of a project's quality or merits, automating the integration of performance metrics across multiple categories was an important step in developing objective assessments. eSPA has also been helpful in facilitating and expediting performance review, program management, and progress reporting.
Project indicators
Indicators that support a direct linkage of improvements in human health and lives saved with specific research projects and portfolios funded by the NIH would be the ideal. However, the incremental nature of most research initiatives coupled with the difficulty in measuring the impact of specific research on human health, requires the consideration of alternative indicators for research evaluation. We identified the following indicator categories for consideration in the eSPA proof-of-concept system:
. productivity: research performance, frequently based on count of primary research publications . quality: importance and significance of research results in creating new knowledge or understanding, usually based on publication citation analysis . dissemination of knowledge: spread of research results, frequently measured by co-authorship networks, collaborations, conference talks
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. vitality of research area: pace of knowledge production in a field, often measured using frequency of highly cited papers or time to first citation for papers in a field . direct economic impact: relevance of research for new product development, for example, acknowledgement of research publications in patents . direct policy impact: relevance of research for public health, for example, citation of research publications by patient treatment guidelines or in Food and Drug Administration (FDA) drug product approval applications.
Based on the literature within the field of scientometrics and program evaluation and discussions with NIAID program staff, an initial set of indicators commonly used as proxies for the listed categories of research evaluation were identified and targeted for collection. These indicators are well known, having been studied, debated, and used in practice for over 40 years (Adams 2005; Garfield 1979; Narin and Hamilton 1996; Ismail et al. 2009 ). They also address GPRA program evaluation criteria (COSEPUP 1999; Knezo 2004) and are responsive to the evaluation objectives used by Marjanovic et al. (2009) . Table 1 lists a brief description of the merits and drawbacks to each indicator implemented in the eSPA proof-of-concept; those in bold are available in the production system. Table 2 lists additional indicators that would be useful but were not included in the study, due to lack of electronic data or linkages to grant data.
Indicator data sources
Numerous sources of useful indicator data are available in electronic form, and although the data sources do not typically include identifiers providing direct links to IMPAC II projects, there is typically enough contextual information to automatically establish links at a high confidence level through custom programming (see Table 3 ). The eSPA production system provides NIH users with access to grants data linked to publications, citations, inventions, patent applications, and patent awards. Of the indicators implemented in the proof-of-concept system, clinical trials and FDA new drug approval data did not support automation of linkages to NIH grants and were The electronic Scientific Portfolio Assistant . 467 not included in the production system (Williams 2007 ). Both of these data sources have had changes to reporting requirements subsequent to the launch of the eSPA production system 5 and NIH is investigating options for eSPA indicators based on these sources.
Databases are usually not built nor maintained for the purpose of linking to grant records and a variety of matching techniques and rules had to be established. In developing the proof-of-concept system, we used a pattern matching algorithm to mine data feed fields and document text for NIH principal investigator names and various forms of grant identification numbers, for example RO1 vs. R01 (a code for NIH grant type) or A1 vs. AI (the two-letter code for NIAID). The eSPA publication links leverage and augments SPIRES publication data with additional matches obtained using alternate text matching and cleansing methods (SPIRES+). Our manual verification process showed that 95% of Medline articles were also listed in Web of Science. We used the NIH funding acknowledgement information from Medline and the citation data from Web of Science to support indicator calculations. As others have found (Boyack and Bo¨rner 2003) , relying on grant acknowledgements can be problematic as investigators may misspell, misreport, or not report their grant number, or journals may not provide for an acknowledgement section wherein this information can be reported. This problem is diminishing for NIH-supported projects because of the public access requirement for peer-reviewed publications, 6 and a recent study reported that a majority of publications funded by NIH grants cite the grant number (Boyack and Jordan 2011).
Analysis interface
The eSPA provides an interactive user interface that supports a faceted search of NIH projects, creation of research portfolios, collaborative review of portfolio content, sharing of portfolios, and iterative analysis of output and outcome indicators. Users can generate plots illustrating trends over time for any of the indicators, or scatter plots comparing indicators such as publication count vs. average citation count per paper. In addition to portfolio reports, users can drill down to the project level by clicking on a grant of interest in any of the portfolio plots or tables. A summary page displays cumulative counts across indicators at the project and portfolio levels. Users can generate lists of publications and patents 
Analyses supported by eSPA: Case studies
NIH has used the eSPA system to build thousands of research portfolios, examine portfolio outputs, and understand program impact. The case studies presented below represent a range of use cases: review and sorting of portfolio content, examination of program outputs, and use of linked input-output data to inform policy. Together they illustrate how, by providing a system to search for projects and collaboratively vet portfolio content, establishing output indicators, and automating the linkage of grants to datasets that support calculation of a variety of output indicators, the eSPA system has: improved the efficiency of the evaluation processes and supported public reporting of outcomes, helped to focus portfolios and thereby steer the research process, and has also provided information which can be used in research management and process.
Evaluation of National Institute of Diabetes and Digestive and Kidney Special Statutory Funding Program for Type 1 Diabetes Research
The NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) portfolio evaluation project is an example of how eSPA meets the NIH objective of improving the efficiency of the evaluation process. It highlights how eSPA has been used to generate project and portfolio performance indicators that satisfy the accountability objectives stated by Marjanovic et al. (2009) 7 NIDDK considered using eSPA to collect outcomes data for a new report, covering the fiscal years [1998] [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] . To understand what data were available in eSPA and their quality and relevance to the proposed evaluation, NIDDK conducted a comparison between the data that were manually collected for the 2007 study and those available through eSPA for the same grants and time parameters.
eSPA was used to collect all papers published in the period 1998-2005 that acknowledged support from any of the grants in the portfolio. In addition, information was collected on the number of citations received by each paper through the end of 2005, as well as US PTO patent applications and issued patents that acknowledged support from any of the grants in the portfolio. Patent applications and issued patents were restricted to those filed or awarded from 2001 to the end of 2005. Because the eSPA data correlated well and were collected in a much shorter time period than the data manually collected for the 2007 study, NIDDK decided to use eSPA to support the 1998-2009 program evaluation report. By using eSPA for the update, NIDDK was able to reduce the cost by nearly ten-fold. The cost savings would have been more except for the cost incurred to first validate the quality of eSPA data and its consistency with what was presented in the original analysis.
In addition to publications, citations, and patents, the second phase of the NIDDK evaluation used eSPA to analyze clinical research activity, resubmission and award of competing grant continuations, and involvement of new investigators for the NIDDK Special Program compared to NIH-wide grant activity. These data were included in their 2010 Progress Report to the US Congress, 8 which describes some of the major scientific advances and future research opportunities that have been made possible by the program.
NIAID HIV vaccine immunology research collaboration
The HIV vaccine immunology research collaboration is an example of the application of the eSPA to test the relevance of portfolio indicators for feeding back into research management processes and steering the research process to desired outcomes.
Development of a preventive vaccine for HIV/AIDS is one of the highest priorities of NIAID and international collaborative efforts (Council of the Global HIV Vaccine Enterprise 2010). An area of growing importance in HIV vaccine research is the development of approaches to induce antibodies that broadly neutralize multiple diverse HIV strains (McMichael et al. 2010) . In 2005, NIAID launched an internal collaboration with the aim of fostering new research between basic immunologists and HIV virologists on the topic of the induction of broadly neutralizing antibodies. Because this represented a new programmatic approach, and because extramural research on HIV and basic immunology are funded and administered in different NIAID divisions (Hackett et al. 2007) , the first task was to assemble a unified portfolio of relevant grants for program staff to identify capabilities, gaps, and potential collaborators. eSPA was used to search for grants, create portfolios, and collaboratively review and sort projects into sub-portfolios.
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The NIAID internal collaboration carried out organizational meetings and brainstorming sessions that led to the following scheme for portfolio establishment:
. Develop a list of key research areas based upon expert consultation. . Perform text-based searches of funded NIAID grants in the IMPAC II database. . Categorize each grant according to its most pertinent research area. . Assemble portfolios corresponding to each research area. . House portfolios in eSPA and apply analytical tools to address needs and evaluate progress.
Six major research areas with sub-areas were defined that encompassed major topics in vaccine-relevant basic immunology of antibody-producing B cells (see Table 4 ). From a list obtained from text searches of IMPAC II using keywords indicative of the defined research areas, program staff determined the relevance of each grant and assigned it to one of the groups and sub-groups. eSPA enabled multiple analyses to be applied to each research area, including the levels of funding; the number of resultant inventions, patent applications, and awarded patents; and the significance of publications.
We found that grants were unevenly distributed among the six research focus areas (see Table 4 ). Particular attention was drawn to the first two areas, where over 50% of the grants were categorized. These categories (B cell repertoire development and lifecycle of responding B cells), address the most basic aspects of B cell biology. Despite the relatively large number of grants in those two areas, only 9% and 3% of grants in those groups, respectively, directly focused on HIV. These results indicated that there was a gap in the application of basic B cell science toward HIV vaccines. Importantly, the analysis also identified a relatively large number of basic immunology investigators who had the potential to collaborate on HIV.
Further analyses of publications in each area helped assess the productivity of projects, and permitted the identification of key advances in the field. An insightful metric proved to be the number of citations versus the total number of recent publications on a per project basis. For example, Figure 1 shows the number of literature citations of articles published from each grant in area 2 as a function of the total number of publications per project in the period 2005-10. This provides a graphic means to rapidly identify grants producing highly cited articles and the projects that supported them, a capability that is of major importance both in focusing research initiatives and in long-term portfolio management. Based in part on this analysis, NIAID took discrete actions to develop collaborations between basic immunologists and HIV researchers. They held seminars and colloquia at national meetings to inform the scientific community of the importance of, and support for, collaborative projects. They also developed funding requests for applications for competitive supplements for existing grants and for new cooperative agreements that led to focusing and expansion of research in the needed areas.
9
The eSPA-based portfolio analysis facilitated program staff in implementing a key objective of research evaluation, namely, to steer the research process toward desired outcomes.
Impact of research policy on the select agents research
The select agents portfolio analysis project shows how output indicators have been combined with funding information in eSPA to study the impact of policy on performance and illustrates how eSPA analyses have informed the research management process.
Select agents are biological agents and toxins that have the potential to pose a severe threat to public, animal or plant health, or to animal or plant products. 10 Research on select agents is tightly regulated, both in terms of handling and disposal of materials, but also in the dissemination of research results and citizenship restrictions on who may be involved in research performance.
11 Dias et al. (2010) conducted a bibliometric analysis of the Bacillus anthracis and Ebola virus archival literature to determine whether negative consequences of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism (USA PATRIOT) Act and the 2002 Bioterrorism Preparedness Act on US select agent research could be discerned. They reported a two-to five-fold increase in the cost of doing select agent research as measured by the number of research papers published per million US research dollars awarded. NIAID analyzed their select agent portfolio using eSPA to corroborate the results (two-to five-fold increase) and better understand the implications for programs.
The key to the eSPA analysis was the ability to create portfolios with defined start dates. Two sets of portfolios were created for the select agents Anthrax and Ebola and non-select agent control Kliebsiella. One set was an established investigator portfolio, containing projects for each agent with a start date prior to 2002 and that continued through 2008. Another set was a new investigator portfolio, containing projects for each agent with a start date after 2002. Having two sets of portfolios with different start dates allowed a more accurate determination of the effect of these Acts on cost per publication.
We were able to replicate the findings of Dias et al. (2010) using eSPA and found a significant increase in cost per publication following the Bioterrorism Preparedness Act of 2002 (see Figure 2) . We conducted additional analyses to determine if other factors may have influenced the increase in cost per publication. A significant influx of new research projects followed the 2002 Act. We considered the maturity of research projects as an additional independent variable. As judged by cost per publication, all new research on both select-and non-select agents is very expensive in the first four to seven years. Costs for Kliebsiella regressed to mean after four years, as did the costs for the established investigator select agent research portfolio. However, costs per publication for the new investigator select agent portfolio are approximately US$200,000 more per publication (see Figure 3) . Together, these findings show that the 2002 Act has increased the cost beyond the expected start-up costs of performing select agents research, specifically for new grants, and may affect the entry of new researchers into the field. Given NIAID's significant investment and leading role in supporting biodefense research, senior managers were interested in these results. By corroborating the observed increase in cost per publication, both the eSPA and Dias et al. (2010) , data were validated. While this result was tempered by the use of differing datasets and choices made in totaling the cost of the research, there was remarkable consistency about how much the cost per publication has increased. The use of the eSPA made further analysis of the dataset very convenient, allowing the analysts to test other independent variables that may have contributed to the observed increase in cost per publication. Ultimately, the analysts concluded that influx of new research projects was likely to have had the greatest influence on the change in cost per publication. The analysis confirmed that the NIAID select agents portfolio was not experiencing unnecessary impediments to research productivity.
Discussion

Findings
The eSPA system, launched in 2008, provides the NIH P&E and program communities with tools for evaluating outputs and outcomes of research projects and portfolios. It provides a workflow for sharing portfolios and vetting workflow content, summary pages for projects and portfolios, an administrative interface for managing users and monitoring system usage, and a tiered security model that allows for gated access to institute-specific data. Corroborating Noyons (2001) , we found that augmenting the eSPA system with support for ad hoc custom analysis was an effective combination for providing automated tools for efficient and trusted analysis, and for testing new requirements for the system.
Use of eSPA has streamlined the process for building grant portfolios, and has automated the linkage of productivity, impact, and innovation outcome indicators to NIH projects and portfolios. By providing a system that links the project search and portfolio building processes Dias et al. (2010) , we found a dramatic increase in cost of conducting select agent research, as measured by cost per publication (using PNAS data), after 2003. After five years costs drop significantly. However, select agent costs, while decreasing, remain high. Kliebsiella costs (used as a control) experienced some variation and then returned to near prior level costs.
with the automation of the previously tedious manual process of linking projects to outputs, eSPA gives users the opportunity to conduct real-time and iterative portfolio evaluation, thereby supporting the NIH goal of improving the efficiency and frequency of program evaluation. eSPA supports GPRA accountability goals by using standard, repeatable methodologies to calculate indicators across projects and portfolios. As illustrated in the case studies, eSPA supports the objectives proposed by Marjanovic et al. (2009) by providing high-quality standardized performance information that can be used by external advocates as well as internal managers to inform research management processes and program policy decisions.
Remaining challenges
While we were able to demonstrate the feasibility of the eSPA system for reporting on numerous project indicators, we were not able to address all identified indicators. In addition to those tested, presumably, there are many other potential indicators of interest, in particular those that provide information on public health impact. Examples include: measuring collaborations, technology transfer, or linkages between funding initiatives and research outcomes. In addition, eSPA could be used to provide validated, organized, visualizable data for hypothesis-developing analyses including: retrospective studies tracing the contribution of various programs to the development of major disease therapies, clinical practice guidelines, and scientific breakthroughs.
Conclusions
Cross-linking scientific knowledge datasets in a systematic fashion provides a unique and useful method for analyzing research productivity across a portfolio and may provide a basis for reporting on portfolio performance. No single indicator will provide a definitive assessment, nor can any single collection of indicators be equally applicable in evaluating all federal agencies, or, for that matter, all NIH institutes. Ideally, a reporting system would allow for the use of indicators specific to an area of research or germane to a funding agency's mission (see discussion in Cozzens (1999) ). Ultimately, we should strive to create evaluation tools that enhance the decision-making process and support the development of a compelling vision for the future of the research enterprise that serves the fundamental needs of our society. Some of this can be attributed to start-up costs, which is confirmed by costs trending lower. However, it is interesting to note that cost remains higher than average in select agent group while cost for control group returns to average within 4-5 years.
